Fig. 2.

Survival graph of all patients. The overall survival (OS) and event-free survival (EFS) rates, which were calculated from the date of transplantation, for all 28 patients are 28.7% (95% confidence interval [CI], 23.1%–45.7%) and 26.3% (95% CI, 13.4%–34.5%), respectively (A). There are no differences in OS and EFS between high-risk and recurrent tumors (B). The OS and EFS rates are significantly higher in patients who achieved complete remission (CR) or partial remission (PR) to prior therapy compared with those in patients who had stable disease (SD) or progressive disease (PD) after prior therapy (C).